Ascendis Pharma A/S (NASDAQ:ASND) Sees Significant Growth in Short Interest

Ascendis Pharma A/S (NASDAQ:ASND) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, an increase of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily trading volume, of 634,100 shares, the days-to-cover ratio is presently 5.4 days.

Ascendis Pharma A/S Trading Up 1.8 %

Ascendis Pharma A/S stock opened at $126.51 on Monday. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66. The firm’s fifty day moving average price is $132.30 and its two-hundred day moving average price is $132.60.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. On average, research analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ASND shares. StockNews.com cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday. Citigroup increased their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after purchasing an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC lifted its position in shares of Ascendis Pharma A/S by 82.3% during the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock valued at $3,391,000 after purchasing an additional 11,223 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Ascendis Pharma A/S by 221.0% during the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after purchasing an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.